erbb 1 genes

Summary

Summary: The proto-oncogene c-erbB-1 codes for the epidermal growth factor receptor. Its name originates from the viral homolog v-erbB which was isolated from an avian erythroblastosis virus (AEV) where it was contained as a fragment of the chicken c-ErbB-1 gene lacking the amino-terminal ligand-binding domain. Overexpression of erbB-1 genes occurs in a wide range of tumors, commonly squamous carcinomas of various sites and less commonly adenocarcinomas. The human c-erbB-1 gene is located in the chromosomal region 7p14 and 7p12.

Top Publications

  1. ncbi Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul, 110 744, South Korea
    Jpn J Clin Oncol 36:344-50. 2006
  2. pmc EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
    Allan R Li
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:242-8. 2008
  3. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
  4. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  5. ncbi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
    Takayuki Kosaka
    Departments of Thoracic Surgery and Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Cancer Res 64:8919-23. 2004
  6. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
  7. ncbi Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
    Ingo K Mellinghoff
    Department of Molecular and Medical Pharmacology and Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles 90095 1732, USA
    N Engl J Med 353:2012-24. 2005
  8. ncbi Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas
    Masahiro Mizoguchi
    Molecular Neuro oncology Laboratory, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Brain Pathol 14:372-7. 2004
  9. ncbi Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours
    A Altimari
    Pathology Unit of the F Addarii Institute of Oncology, Department of Oncology and Hematology, University of Bologna, Viale Ercolani 412, 40138 Bologna, Italy
    Dig Liver Dis 35:332-8. 2003
  10. ncbi An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    Maria L Amador
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Res 64:9139-43. 2004

Detail Information

Publications178 found, 100 shown here

  1. ncbi Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul, 110 744, South Korea
    Jpn J Clin Oncol 36:344-50. 2006
    ..We retrospectively analyzed the associations between response to chemotherapy and molecular markers associated with gefitinib responsiveness including EGFR mutations...
  2. pmc EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
    Allan R Li
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:242-8. 2008
    ..Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status...
  3. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..These results suggest that EGFR mutations may predict sensitivity to gefitinib...
  4. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown...
  5. ncbi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
    Takayuki Kosaka
    Departments of Thoracic Surgery and Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Cancer Res 64:8919-23. 2004
    ..EGFR mutations define a distinct subset of pulmonary adenocarcinoma without KRAS mutations, which is not caused by tobacco carcinogens...
  6. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
    ..However, the role of such mutations in the pathogenesis of lung cancers is unclear...
  7. ncbi Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
    Ingo K Mellinghoff
    Department of Molecular and Medical Pharmacology and Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles 90095 1732, USA
    N Engl J Med 353:2012-24. 2005
    ..The mechanism of responsiveness of glioblastomas to these inhibitors is unknown...
  8. ncbi Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas
    Masahiro Mizoguchi
    Molecular Neuro oncology Laboratory, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Brain Pathol 14:372-7. 2004
    ..These results suggest that genetic alterations of class IA PI3K subunit genes can occasionally play a role in human glioblastoma by activating the PI3K-AKT signaling pathway independently of PTEN mutation...
  9. ncbi Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours
    A Altimari
    Pathology Unit of the F Addarii Institute of Oncology, Department of Oncology and Hematology, University of Bologna, Viale Ercolani 412, 40138 Bologna, Italy
    Dig Liver Dis 35:332-8. 2003
    ..Molecular targets are needed for primary liver tumours...
  10. ncbi An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    Maria L Amador
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Res 64:9139-43. 2004
    ....
  11. pmc Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
    Alejandro Wolf-Yadlin
    Biological Engineering Division, MIT, Cambridge, MA, USA
    Mol Syst Biol 2:54. 2006
    ..Combining these modeling approaches enabled association of epidermal growth factor receptor family dimerization to activation of specific phosphorylation sites, which appear to most critically regulate proliferation and/or migration...
  12. ncbi Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
    Adi F Gazdar
    Hamon Centre for Therapeutic Oncology Research, University of Texas Southwestern Medical Centre, Dallas, TX 75390, USA
    Trends Mol Med 10:481-6. 2004
    ..Cancer cells with mutant EGFR genes might become physiologically dependent on the continued activity of the gene for the maintenance of their malignant phenotype; however, this might also be a target for therapy...
  13. ncbi Biological and clinical implications of EGFR mutations in lung cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, 464 8681, Japan
    Int J Clin Oncol 11:190-8. 2006
    ..These populations precisely coincide with those populations with higher response rates to TKIs. We and others subsequently confirmed and extended these findings...
  14. ncbi Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study
    Horst Buerger
    Institute of Pathology, University of Munster, Albert Schweitzer Strasse 33, 48139 Münster, Germany
    J Pathol 203:545-50. 2004
    ..This new knowledge about mechanisms of regulation of EGFR expression might serve as an additional basis for evaluating anti-EGFR-based therapies...
  15. ncbi Somatic mutations of EGFR in colorectal cancers and glioblastomas
    Thomas D Barber
    N Engl J Med 351:2883. 2004
  16. ncbi Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    Cancer Res 65:1642-6. 2005
    ..EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers...
  17. ncbi Identification of a second egfr gene in Xiphophorus uncovers an expansion of the epidermal growth factor receptor family in fish
    Ana Gomez
    Physiological Chemistry I, Theodor Boveri Institute for Biosciences Biocenter, University of Wurzburg, Wurzburg, Germany
    Mol Biol Evol 21:266-75. 2004
    ..The mechanism of maintenance of these duplicates remains to be clarified...
  18. ncbi Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Res 66:1371-5. 2006
    ..Our results indicate the differences in the evolvement of epigenetic alterations between the EGFR- and K-RAS-mediated tumorigenesis and suggest the specific interaction of genetic and epigenetic changes in tumorigenesis of lung cancer...
  19. ncbi Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
    Makoto Suzuki
    Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan
    Cancer 106:2200-7. 2006
    ..Both genetic and epigenetic changes in nonsmall cell lung cancer (NSCLC) are known to be a common event...
  20. ncbi Candidate genes colocalized to linkage regions in inflammatory bowel disease
    K Martin
    Medizinische Klinik, Standort Innenstadt, Ludwig Maximilians Universitat Munchen, Deutschland
    Digestion 66:121-6. 2002
    ..An association study of these gene polymorphisms with ulcerative colitis or Crohn's disease and a stratification according to disease phenotypes was performed in order to identify genetically homogenous subgroups...
  21. ncbi Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells
    Mitsuo Sato
    Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas 75390 8593, USA
    Cancer Res 66:2116-28. 2006
    ....
  22. ncbi Cancer. A bull's eye for targeted lung cancer therapy
    John D Minna
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Science 304:1458-61. 2004
  23. ncbi EGFR gene and protein expression in breast cancers
    K Park
    Department of Pathology, Inje University Sanggye Paik Hospital, 761 1 Sanggye Dong, Nowon Gu, Seoul, South Korea
    Eur J Surg Oncol 33:956-60. 2007
    ..To measure the EGFR gene amplification and protein expression, and to compare the EGFR expression with HER2 expression similarly measured...
  24. ncbi Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer
    C M Chen
    Department of Imaging and Intervention, and Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Acta Radiol 49:991-4. 2008
    ..Target therapy with a new class of epidermal growth factor receptor (EGFR) inhibitors shows improved clinical response in EGFR gene-mutated lung cancers...
  25. ncbi Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
    Tianhong Li
    Department of Oncology, Montefiore Medical Center and the Albert Einstein Cancer Center, Bronx, NY 10461, USA
    J Thorac Oncol 3:643-7. 2008
    ....
  26. ncbi Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer
    Paweł Krawczyk
    Pulmonary Department, Medical University of Lublin, Lublin, Poland
    Ann Univ Mariae Curie Sklodowska Med 58:113-7. 2003
    ..Phase III Tarceva clinical trail in NSCLC patients showed that their survival is prolonged and that the medication acts together with other chemotherapeutic agents like cisplatin and gemcitabine...
  27. ncbi Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 26:2745-53. 2008
    ..To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment...
  28. ncbi [Molecular targeted therapy--non-small-cell lung cancer and gefitinib]
    Junichi Shimizu
    Dept of Thoracic Oncology, Aichi Cancer Center Central Hospital
    Gan To Kagaku Ryoho 32:1879-85. 2005
    ....
  29. ncbi Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer
    G Kesava Reddy
    Clin Lung Cancer 7:163-5. 2005
  30. ncbi Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 0021, Japan
    Gen Thorac Cardiovasc Surg 56:97-103. 2008
    ..Based on this concept, Phase III clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy are currently ongoing for patients with EGFR mutations and lung cancer...
  31. ncbi Predicting response of molecular targeted therapies: a still possible challenge?
    R Labianca
    Ann Oncol 19:829-30. 2008
  32. ncbi EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients
    Ximing Tang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 65:7568-72. 2005
    ..Our findings indicate that mutation of the tyrosine kinase domain of EGFR is an early event in the pathogenesis of lung adenocarcinomas, and suggest EGFR mutations as an early detection marker and chemoprevention target...
  33. ncbi Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:7525-9. 2005
    ....
  34. ncbi Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
    Yoshiaki Nagai
    Department of Respiratory Medicine, Saitama Medical School, Moroyama machi, Iruma gun, Saitama, Japan
    Cancer Res 65:7276-82. 2005
    ..Genetic heterogeneity of EGFR suggests that the EGFR gene is unstable in established cancers and the heterogeneity may explain variable clinical responses of lung cancers to gefitinib...
  35. ncbi Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Chang Qi Zhu
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 26:4268-75. 2008
    ..To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial...
  36. ncbi An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
    Cancer Res 65:7096-101. 2005
    ..These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation...
  37. ncbi Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, TX 78229, USA
    Clin Lung Cancer 6:S35-42. 2004
    ..The result should be more efficient and scientifically founded clinical development strategies for rationally designed target-based therapeutic agents...
  38. ncbi Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    Cancer Invest 26:784-93. 2008
    ..The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer...
  39. ncbi [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]
    J Madelaine
    Rev Mal Respir 21:881-5. 2004
  40. ncbi A molecular chink in the lung cancer armour
    K M Fong
    Respirology 9:426-7. 2004
  41. ncbi First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S143-5. 2008
    ..This review summarizes the data describing the use of EGFR tyrosine kinase inhibitors in a genotype-directed population of NSCLC patients with EGFR mutations and discusses areas that require further study...
  42. ncbi Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
    Myung Ju Ahn
    Division of Hematology Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    Clin Cancer Res 14:3860-6. 2008
    ..This study investigated possible molecular predictors of outcome in Korean patients with advanced non-small cell lung cancer treated with erlotinib...
  43. ncbi [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer]
    Ren Sheng Lai
    Zhonghua Bing Li Xue Za Zhi 34:745-6. 2005
  44. pmc High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
    D W Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Br J Cancer 98:1118-24. 2008
    ..In conclusion, tumour islet macrophage infiltration was identified as a strong favourable independent prognostic marker for survival but not correlated with the molecular changes of the EGFR in patients with resected NSCLC...
  45. ncbi Race, gender and mutations in the prediction of anti-EGFR activity
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Drug Development Program, Oncology Department, The Bunting Blaustein Cancer Research Building, Room 162A, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Future Oncol 1:201-4. 2005
    ..Evaluation of: Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64(24), 8919-8923 (2004)...
  46. ncbi [A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib]
    Hisao Imai
    Department of Respiratory Medicine, The National Hospital Organization Nishi gunma Hospital
    Nihon Kokyuki Gakkai Zasshi 45:189-93. 2007
    ..After starting gefitinib and discontinuing the NSAID, She had kept a remission of rational symptom with cytoreductive effect. The abnormal findings of bone scintigrams subsequently disappeared and the patient's serum ICTP dropped...
  47. ncbi Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells
    Christopher Y Thomas
    Division of Hematology Oncology, Mayo Clinic Jacksonville, Mayo Medical School, Jacksonville, Jacksonville, FL, USA
    Int J Cancer 104:19-27. 2003
    ..The results also suggest that in some GBMs, signals from overexpressed EGFRs contribute to the constitutive phosphorylation of Erk, but these signals may not required for the constitutive activation of PI3K or AKT1...
  48. pmc Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
    A Sutani
    Department of Respiratory Medicine, Saitama Medical University, Iruma gun, Saitama 350 0495, Japan
    Br J Cancer 95:1483-9. 2006
    ..0135). A Cox proportional hazards model indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P = 0.036). This research showed the need for screening for EGFR mutations in NSCLC patients...
  49. pmc Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer
    Xiaozhu Zhang
    Division of Biomedical Sciences, Johns Hopkins Singapore, 31 Biopolis Way, 02 01, The Nanos, Singapore 138669, Singapore
    J Med Genet 44:166-72. 2007
    ..This brief review summarises the discovery and functional consequences of the mutations, their clinicopathological features and significant implications in the treatment and prognosis of NSCLC...
  50. ncbi Molecular signatures of lung cancer--toward personalized therapy
    Roy S Herbst
    N Engl J Med 356:76-8. 2007
  51. ncbi Managing dermatologic toxicities of epidermal growth factor receptor inhibitors
    Lillian S Chou
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 8:S15-22. 2006
    ..D. Anderson Cancer Center have been positive, and there is universal agreement that initiation of more prospective trials to evaluate EGFR-inhibitor rash management is needed...
  52. ncbi [Gefitinib and epidermal growth factor receptor gene mutation]
    Takayuki Fukui
    Dept of Thoracic Surgery, Aichi Cancer Center Hospital, Japan
    Gan To Kagaku Ryoho 34:1168-72. 2007
    ..Based on this concept, phaseIII clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy in lung cancer patients with EGFR mutations are ongoing...
  53. pmc Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
    Masaharu Nomura
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS Med 4:e125. 2007
    ..The objective of this study was to examine distributions of these three polymorphisms and their relationships to each other and to EGFR gene mutations and allelic imbalance (AI) in non-small cell lung cancers...
  54. ncbi Prevalence of mutation in the epidermal growth factor receptor gene in Chinese patients with non-small cell lung cancer
    B Jiang
    Clin Oncol (R Coll Radiol) 18:635. 2006
  55. ncbi Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation
    Amit K Das
    Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, 2201 Inwood Road, NC 7 208, Mail Code 9187, Dallas, TX 75390, USA
    Cancer Res 66:9601-8. 2006
    ....
  56. ncbi Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer
    Hidefumi Sasaki
    Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    J Cancer Res Clin Oncol 134:569-77. 2008
    ..The EGFR mutation status, especially exon19 mutation was correlated with good response to gefitinib than exon 21 point mutation...
  57. ncbi Erlotinib in non-small cell lung cancer treatment: current status and future development
    Cesare Gridelli
    Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
    Oncologist 12:840-9. 2007
    ....
  58. ncbi From the bench to the bed: individualizing treatment in non-small-cell lung cancer
    Mariacarmela Santarpia
    Medical Oncology Unit, University of Messina, Messina, Italy
    Clin Transl Oncol 8:71-6. 2006
    ..EGFR tyrosine kinase mutations are the crux of targeted therapies...
  59. ncbi Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes
    Wen Chi Chou
    Department of Hematology Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
    Jpn J Clin Oncol 36:523-6. 2006
    ..This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance...
  60. ncbi Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma
    Naoki Hijiya
    Department of Molecular Pathology, Oita University Faculty of Medicine, Oita 879 5593, Japan
    Hum Pathol 39:316-23. 2008
    ..0011). These findings suggest that immunohistochemical evaluation with anti-pEGFR-tyr992 antibody is useful for prediction of responsiveness to gefitinib...
  61. ncbi Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 110:2775-84. 2007
    ..Therefore, it was hypothesized that tumor EGFR mutation status may influence the effectiveness of simultaneous EGFR and COX-2 inhibition in patients with NSCLC...
  62. ncbi Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors
    R K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cold Spring Harb Symp Quant Biol 70:73-81. 2005
    ..In summary, by applying high-throughput genomic resequencing, we have identified a novel therapeutic target, mutant EGFR, in lung cancer and evaluated its role in predicting response to targeted therapy...
  63. ncbi Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:632-7. 2007
    ..The aim of this study was to clarify its association. We also examined whether this association could be affected by previous gefitinib treatment...
  64. ncbi Transferrin receptor hyperexpression in primary erythroblasts is lost on transformation by avian erythroblastosis virus
    Lioba Lobmayr
    Institute of Medical Biochemistry, Division of Molecular Biology, Vienna Biocenter, Vienna, Austria
    Blood 100:289-98. 2002
    ..In summary, stabilization of TfR mRNA and redistribution of Fe-Tf/TfR complexes to late endosomal compartments may contribute to TfR hyperexpression in primary erythroblasts, effects that are lost on leukemic transformation...
  65. ncbi Avian retroviral vectors derived from avian defective leukemia virus: role of the translational context of the inserted gene on efficiency of the vectors
    M Benchaibi
    Laboratoire de Biologie, Ecole Normale Superieure de Lyon, France
    Virology 169:15-26. 1989
    ..Our data provide information for further construction of double expression vectors. Furthermore, three of the vectors would provide helpful tools to identify genetic elements of the virus genome involved in splicing regulation...
  66. pmc Tyrosine kinase activity may be necessary but is not sufficient for c-erbB1-mediated tissue-specific tumorigenicity
    D C Connolly
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905
    J Virol 68:6804-10. 1994
    ....
  67. ncbi v-erbB oncogene expression accounts for most variations in protein synthesis after avian erythroblastosis virus infection of chicken embryo fibroblasts: a two-dimensional electrophoresis study
    C Desbois
    Immuno Virologie Moleculaire et Cellulaire, Universite Claude Bernard, CNRS UMR 30, Faculte de Medicine Alexis Carrel, Lyon, France
    Electrophoresis 13:383-8. 1992
    ..Moreover, the deregulation of protein synthesis by v-erbB-expressing viruses was correlated with the morphological transformation state of cells...
  68. ncbi Transforming genes from familial adenomatous polyposis patient cells detected by a tumorigenicity assay
    Y Yuasa
    Department of Hygiene and Oncology, School of Medicine, Tokyo Medical and Dental University, Japan
    Oncogene 5:589-96. 1990
    ..This gene did not hybridize with the met and erbB1 genes, which are potential oncogenes located on chromosome 7. These data indicate that this gene is a new oncogene...
  69. ncbi Cell signaling modifiers in prostate cancer
    Franklin L Chen
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer J 14:40-5. 2008
    ..Further investigation is necessary for the targeted inhibition of receptor tyrosine kinases and mTOR in HRPC. However, these classes of drugs may prove efficacious as tumoricidal agents or as chemo- and radiosensitizers...
  70. ncbi Molecular genetic changes in a series of neuroepithelial tumors of childhood
    Alessia Di Sapio
    Divisione Universitaria di Neurologia, Ospedale San Luigi, Torino, Italy
    J Neurooncol 59:117-22. 2002
    ....
  71. ncbi Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Japan
    Clin Cancer Res 15:907-13. 2009
    ..We have now investigated whether addition of the oral fluoropyrimidine derivative S-1 to gefitinib might overcome gefitinib resistance in NSCLC cell lines...
  72. pmc EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
    G Pines
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
    Oncogene 29:5850-60. 2010
    ..This information, along with remarkable sensitivities to tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological interception in brain tumors harboring EGFRvIV mutations...
  73. ncbi PIK3CA mutation status in Japanese lung cancer patients
    Osamu Kawano
    Department of Surgery II, Nagoya City University Medical School, Nagoya, Japan
    Lung Cancer 54:209-15. 2006
    ..PIK3CA gene mutations were rare in lung cancer; rarer in adenocarcinoma. Further functional analyses of the PIK3CA mutations are warranted to study if they could be the target of therapy for the lung cancer...
  74. ncbi The new generation of targeted therapies for breast cancer
    Samira Syed
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Sciences Center, USA
    Oncology (Williston Park) 17:1339-51; discussion 1352, 1355-6. 2003
    ..This article reviews the development of several novel targeted therapies that may be efficacious in the treatment of patients with breast cancer and highlights the challenges and opportunities associated with these agents...
  75. ncbi Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer
    Makoto Sonobe
    Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
    J Surg Oncol 95:63-9. 2007
    ..In this paper we examined the influence of epidermal growth factor receptor (EGFR) gene mutations on EGFR expression, downstream mediators, and survival in patients with non-small cell lung cancer (NSCLC)...
  76. ncbi Morphological assessment of the development of multinucleated giant cells in glioma by using mitosis-specific phosphorylated antibodies
    Kenkou Maeda
    Department of Neurosurgery, Nagoya University Graduate School of Medicine, Japan
    J Neurosurg 98:854-9. 2003
    ..To investigate the phosphorylation of intermediate filaments, the authors studied multinucleated giant cells in vitro and in vivo by using mitosis-specific phosphorylated antibodies...
  77. ncbi EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer
    Jonathan E Dowell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Nat Clin Pract Oncol 3:170-1. 2006
  78. pmc Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment
    Jay M Lee
    Division of Cardiothoracic Surgery, Department of Surgery, UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Crit Rev Oncol Hematol 66:208-17. 2008
    ..The understanding of molecular mechanisms involved in inflammation and lung carcinogenesis provide insight for new drug development that target reversible, non-mutational events in the chemoprevention and treatment of lung cancer...
  79. ncbi Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma
    Yukitaka Ushio
    Department of Neurosurgery, Kumamoto University Medical School, Kumamoto, Japan
    Front Biosci 8:e281-8. 2003
    ..Further studies on large cohorts are necessary to elucidate the genetic factors that affect the prognosis and response to therapy of patients with malignant gliomas and to develop effective management strategies...
  80. ncbi [Molecular targeted therapy and tailor-made therapy for lung cancer]
    Kenji Sugio
    Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan
    Kyobu Geka 61:37-42. 2008
    ..Molecular targeted therapy using TKI indicates an effective therapy specifically in lung cancer patients with EGFR mutations, and analyses of mechanisms of resistance to TKI are necessary for establishment of tailor-made therapy...
  81. pmc Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers
    Marie Pierre Buisine
    Centre de Recherche Jean Pierre Aubert, INSERM U837, Place de Verdun, 59045 Lille Cedex, France
    World J Gastroenterol 14:1053-9. 2008
    ....
  82. ncbi Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses
    Maricris Macabeo-Ong
    Oral Pathology, Department of Stomatology, University of California San Francisco, California 94143 0424, USA
    Mod Pathol 15:979-87. 2002
    ..However, results for some markers are adversely affected by prolonged formalin fixation times...
  83. ncbi Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients
    Y Lemos-González
    Department of Biochemistry, Genetics and Immunology, University of Vigo, Vigo, Spain
    Tumour Biol 28:273-9. 2007
    ..Additional investigations about EGFR amplification are indicated to establish a potential relationship between EGFR overexpression and the response to anti-EGFR therapies...
  84. ncbi Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval
    Ramon Martinez
    Department of Neurosurgery, University of Dresden, Germany
    Brain Pathol 13:598-607. 2003
    ..Whether the molecular features of the first glioblastoma are associated with the notably extended recurrence-free period of 5 years remains to be elucidated...
  85. ncbi [Growth factors of the EGF family and their receptors]
    Pierre Hubert
    Laboratoire d Ingénierie des Systèmes Macromoléculaires LISM, UPR 9027 du CNRS, Institut de Biologie Structurale et Microbiologie, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20
    Bull Cancer 94:F137-45. 2007
    ..The oncogenic alterations of the growth factor--receptor interaction are multiple and constitute several potential targets for therapeutic development...
  86. ncbi Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus
    Agnieszka M Rygiel
    Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 17:1380-5. 2008
    ..Gains of the loci might be of value as prognostic markers because they are already present in nondysplasia cases and may precede the later event of the amplification as observed in high-grade dysplasia and esophageal adenocarcinoma...
  87. pmc In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation
    Giovanni Perini
    Department of Biology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
    Proc Natl Acad Sci U S A 102:12117-22. 2005
    ..This study illuminates a central role of DNA methylation in controlling N-Myc occupancy at gene promoters and modulating its transcriptional activity in cancer cells...
  88. pmc Host-based antipoxvirus therapeutic strategies: turning the tables
    Anthony S Fauci
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892 2520, USA
    J Clin Invest 115:231-3. 2005
    ..Drugs that target the ErbB-signaling pathways represent a promising new class of antiviral agents...
  89. ncbi Novel biomarkers of metastatic cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
    Expert Rev Mol Diagn 10:581-90. 2010
    ..DNA- and RNA-based biomarkers have also been identified. This review will focus on some of the novel biomarkers that have been developed over the last decade...
  90. ncbi IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo
    Andrea Kröger
    Department of Gene Regulation and Differentiation, GBF German Research Center for Biotechnology, Mascheroder Weg 1, D 38124 Braunschweig, Germany
    Oncogene 22:1045-56. 2003
    ..Inhibition of tumor growth is observed in nude mice as long as IRF-1 is active, indicating that neither B- nor T-cells must become activated for tumor growth suppression...
  91. ncbi Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
    ..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation...
  92. ncbi The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer
    Emmet McIntyre
    Computing Laboratory, University of Kent, Canterbury, Kent CT1 7NJ, UK
    Breast Cancer Res Treat 122:105-10. 2010
    ..Analysing the data using the Cox Proportional Hazards model showed that, in this dataset, the most powerful predictors of relapse free interval and overall survival were the combined measurement of only Epigen and Neuregulin 4...
  93. ncbi Transgenic and knock-out mice for deciphering the roles of EGFR ligands
    R W C Wong
    Department of Anatomy and Cell Biology, Graduate School of Medicine, University of Tokyo, Tokyo 113 0033, Japan
    Cell Mol Life Sci 60:113-8. 2003
    ..Finally, future investigations on ligand-ligand communications, EGFR and its ligands in neural stem cell research, and the mechanisms of EGFR signaling and trafficking in cells are also suggested...
  94. pmc rugose (rg), a Drosophila A kinase anchor protein, is required for retinal pattern formation and interacts genetically with multiple signaling pathways
    Hoda K Shamloula
    Department of Biology, City College and The Graduate Center, City University of New York, New York 10031, USA
    Genetics 161:693-710. 2002
    ..Our results suggest that rg is required for correct retinal pattern formation and may function in cell fate determination through its interactions with the EGFR and Notch signaling pathways...
  95. pmc Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
    Kimio Yonesaka
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:6963-73. 2008
    ..The determinant(s) of efficacy of EGFR-targeted therapies in EGFR wild-type cancers is not well defined...
  96. pmc MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
    F Cappuzzo
    Department of Oncology Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    Ann Oncol 20:298-304. 2009
    ..MET amplification has been detected in approximately 20% of non-small-cell lung cancer patients (NSCLC) with epidermal growth factor receptor (EGFR) mutations progressing after an initial response to tyrosine kinase inhibitor (TKI) therapy...
  97. ncbi The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma
    Abbas Ghaderi
    Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
    Pathol Oncol Res 8:252-6. 2002
    ..Moreover, the relatively high percentage of c-erbB-2 positive tumors may provide a useful target for the immunotherapy of these cancers...
  98. pmc The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer
    Carlynn Willmore-Payne
    Associated Regional and University Pathologists Institute for Clinical and Experimental Patholog y, Salt Lake City, UT 84108, USA
    J Biomol Tech 19:217-24. 2008
    ..This allows for easy identification of activating mutations even in homozygous or amplified states and is useful in the screening of NSCLC for the common EGFR activating mutations...
  99. ncbi Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung
    Toshiyuki Kozuki
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 58:30-5. 2007
    ..Although EGFR mutations appeared to be partially associated with the early steps of adenocarcinoma development, such mutations may possibly occur randomly even in multiple lesions in a single patient...
  100. ncbi Chromosomal assignment of the two candidate genes (EGFR, CLCA1) for equine recurrent airway obstruction (RAO) by FISH and RH mapping
    J Klukowska-Rötzler
    Equine Clinic, Department of Veterinary Clinical Studies, Vetsuisse Faculty, University of Berne, PO Box 8466, CH 3001 Berne, Switzerland
    Hereditas 143:138-41. 2006
  101. ncbi Association between the length of a CA dinucleotide repeat in the EGFR and risk of breast cancer
    Mohammad Saeid Jami
    Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jarib, Isfahan, Iran
    Cancer Invest 26:434-7. 2008
    ..86. We have also found that women with short alleles (< 19) had much greater risk of developing cancer before the age of 55 (OR, 3.36)...

Research Grants15

  1. RRM1/PTEN Axis in Non-Small Cell Lung Cancer
    Gerold Bepler; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  2. UNIQUE TISSUE AND TUMOR PROCESSING FACILITY
    Adi Gazdar; Fiscal Year: 2003
    ..A charge back fee system will recover some of the costs and will be used for future expansion of the Facility, which is anticipated to become self sustaining after five years. ..
  3. MOLECULAR PATHOGENESIS OF MALIGNANT MELANOMA
    Lynda Chin; Fiscal Year: 2002
    ....
  4. Genomic & Genetic Characterization of Amplicons in GBMs
    Lynda Chin; Fiscal Year: 2007
    ..The highest potential candidate glioma oncogene will be further validated by rigorous in vivo transgenesis study. ..
  5. Radiosensitization with the HIV protease inhibior Nelfinavir in NSCLC
    Anjali Gupta; Fiscal Year: 2008
    ..Specific Aim 3. To investigate in vitro the molecular mechanisms by which NFV results in sensitization. [unreadable] [unreadable] [unreadable]..
  6. Exisulind for Chemoprevention of Lung Cancer
    Gerold Bepler; Fiscal Year: 2007
    ..The data generated by these investigations will be important for future decisions on large-scale chemoprevention trials using disease incidence and mortality as endpoints. ..
  7. Immunotherapy for gliomas with monoclonal antibodies targeting MCSP
    Robert Fenstermaker; Fiscal Year: 2007
    ..This proposal fits with the overall goal of our research program which is centered on the development of targeted immunotherapeutic strategies to treat malignant gliomas. [unreadable] [unreadable]..
  8. Cs-137 Irradiator for new Fitzsimons Campus
    David Raben; Fiscal Year: 2007
    ..The JL 81 irradiator is an important component of this foundation of cancer research and will facilitate the preclinical experiments necessary for translation at the new UCDHSC Fitzsimons campus. [unreadable] [unreadable] [unreadable]..
  9. Pharmacogenomics of Neoadjuvant Gemcitabine-Pemetrexed *
    Gerold Bepler; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  10. Molecular Pathology of Lung Cancer
    John Minna; Fiscal Year: 2005
    ..The group of speakers who have agreed to participate are some of the leading transdisciplinary investigators in these fields and are active in seeking to translate their findings to and from the clinic and the laboratory. ..
  11. Targeting the anti-apoptotic protein survivin in glioma
    Robert Fenstermaker; Fiscal Year: 2005
    ..The purpose of the pre-clinical studies outlined here is to investigate the potential for the development of antisurvivin vaccines for eventual clinical investigation in the treatment of human gliomas. ..
  12. Characterization of Human 3p Recessive Oncogenes
    John Minna; Fiscal Year: 2004
    ..The characterization of these gene(s) should ultimately have translational benefit for the development of new cancer diagnostics and therapeutics, including use in cancer early detection, prevention, and treatment. ..
  13. The 7th International Conference on Head and Neck Cancer
    Jeffrey Myers; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  14. Molecular Determinants of Acquired Erlotinib Resistance
    Vincent Miller; Fiscal Year: 2006
    ..abstract_text> ..
  15. A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
    Vincent Miller; Fiscal Year: 2008
    ..The proposed work is a clinical trial to determine whether dasatinib is an effective treatment for patients with NSCLC and acquired resistance to erlotinib or gefitinib. [unreadable] [unreadable] [unreadable]..